TiGenix is licensing the rights for its cell therapy which is under EMA review and is meant to treat a serious complication of Crohn’s disease. This worldwide exclusivity deal (with exception to the US) could be worth up to €380M.
Back in 2009, Leuven-based TiGenix was the first to launch at cell-based product (ChondroCellect) on the European market. The Biotech currently develops stem cell therapies for different autoimmune and inflammatory diseases.
Its most advanced clinical program is Cx601, which has completed Phase III trials almost one year ago, and is now under EMA review. The therapy consists of stem cells derived from the adipose tissue of donors (allogeneic), designed to treat complex perianal fistulas in Crohn’s disease patients, for which there is currently no effective treatment.
Cx601 has now attracted the attention of Takeda, the largest Japanese Pharma, which is paying €25M upfront for the rights to develop and commercialize the therapy everywhere except in the US. Milestone payments could go up to €355M.